SPRINT-TB
  • Home
  • About
    • About Us
    • Annual Report
    • Scientific Advisory Board
    • Funders
  • Research
    • Theme 1: Target Discovery
    • Theme 2: Drug Development
    • Theme 3: Clinical Trials
    • Theme 4: Treatment Delivery
  • News
  • Events
    • Journal Club
    • Annual Symposium
  • Giving
  • Contact
    • Contact
    • Careers

Bortezomib Shows Potential for Tuberculosis Treatment

3/3/2015

0 Comments

 
PictureNUS inventors of repurposed use of bortezomib: Dr. Wilfried Moreira and A/Prof. Thomas Dick.
SPRINT-TB Theme 1 researchers identified bortezomib (or Velcade®, which is currently approved for treatment of multiple myeloma), as a novel whole-cell active mycobacterial caseinolytic protease (Clp) inhibitor. Clp constitutes a key degradative proteolytic machinery involved in central proteome homeostasis in Mycobacteria. Clp was found to be potently inhibited by bortezomib and its derivatives, followed by mycobacterial growth inhibition. The discovery established Clp as a new validated drug target and bortezomib as an attractive lead compound for the development of new tuberculosis drugs. Bortezomib and its derivatives are currently under further pre-clinical investigation. 

A provisional patent application for the repurposed use of bortezomib was filed on February 6, 2015. This invention is a product of collaboration between Eric Rubin’s group at Harvard School of Public Health (USA), the Experimental Therapeutic Center - A*STAR (Singapore) and Thomas Dick’s group at Department of Microbiology, National University of Singapore (Singapore).

0 Comments

    Archives

    September 2018
    December 2017
    March 2017
    December 2016
    September 2016
    March 2016
    February 2016
    December 2015
    November 2015
    October 2015
    September 2015
    July 2015
    May 2015
    April 2015
    March 2015
    February 2015
    November 2014
    October 2014
    September 2014
    July 2014

    Categories

    All

    RSS Feed

Picture
Home | About | Research | News | Events | Contact
Intranet
Terms & Conditions
Copyright © 2014-2017 SPRINT-TB. All Rights Reserved.